Novel type II fatty acid biosynthesis (FAS II) inhibitors as multistage antimalarial agents.

ABSTRACT: Malaria is a potentially fatal disease caused by Plasmodium parasites and poses a major medical risk in large parts of the world. The development of new, affordable antimalarial drugs is of vital importance as there are increasing reports of resistance to the currently available therapeutics. In addition, most of the current drugs used for chemoprophylaxis merely act on parasites already replicating in the blood. At this point, a patient might already be suffering from the symptoms associated with the disease and could additionally be infectious to an Anopheles mosquito. These insects act as a vector, subsequently spreading the disease to other humans. In order to cure not only malaria but prevent transmission as well, a drug must target both the blood- and pre-erythrocytic liver stages of

SUBMITTER: Schrader FC 

PROVIDER: S-EPMC3633473 | biostudies-literature | 2013 Mar

REPOSITORIES: biostudies-literature